Apixaban, an oral, direct inhibitor of activated Factor Xa

Eduard Shantsila, Gregory Lip

Research output: Contribution to journalArticle

45 Citations (Scopus)


Apixaban is an oral, direct Factor Xa inhibitor that is being developed by Bristol-Myers Squibb Co and Pfizer Inc. Apixaban is currently undergoing phase III clinical trials for cerebrovascular ischemia, deep vein thrombosis and lung embolism, and phase II clinical trials for coronary artery disease.
Original languageEnglish
Pages (from-to)1020-33
Number of pages14
JournalCurrent Opinion in Investigational Drugs
Issue number9
Publication statusPublished - 1 Sept 2008


Dive into the research topics of 'Apixaban, an oral, direct inhibitor of activated Factor Xa'. Together they form a unique fingerprint.

Cite this